Monopar Therapeutics

Company Overview

Monopar Therapeutics is a clinical-stage biotechnology company developing novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease, a rare genetic disorder. Its pipeline includes radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease. The radiopharma programs targeting advanced cancers include clinical-stage MNPR-101-Zr for imaging, and for therapy, clinical-stage MNPR-101-Lu and late-preclinical stage MNPR-101-Ac. Monopar builds its drug development pipeline through in-house efforts and licensing of late preclinical and clinical-stage therapeutics, leveraging its scientific and clinical expertise to reduce risk and accelerate development.

Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data

Nov 2 2026, 8:00 AM EST

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

Aug 19 2026, 8:00 AM EDT

Stock Overview

Symbol	MNPR
Exchange	Nasdaq
Market Cap	444.88m
Last Price	$66.28
52-Week	$50.07 - $124.82

11/02/2026 09:00 PM EST

Management Team

Chandler D. Robinson, MD MBA MSc
Co-Founder, Chief Executive Officer and Board Member

Christopher M. Starr, PhD
Co-Founder and Executive Chairman of the Board

Quan Vu
Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer

Monopar Therapeutics Inc.

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.